Rosiglitazone (Avandia)

A thiazolidinedione that functions as a selective agonist for PPAR GAMMA. It improves INSULIN SENSITIVITY in adipose tissue, skeletal muscle, and the liver of patients with TYPE 2 DIABETES MELLITUS.

Also Known As:

Avandia; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; BRL 49653; BRL-49653; BRL49653; Rosiglitazone Maleate; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-

Networked: 2780 relevant articles (374 outcomes, 703 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cha, Bong Soo: 16 articles (01/2013 - 01/2005)
2.	Derosa, Giuseppe: 15 articles (01/2018 - 05/2004)
3.	Kang, Eun Seok: 15 articles (02/2016 - 05/2005)
4.	Lee, Hyun Chul: 15 articles (01/2013 - 01/2005)
5.	TODAY Study Group: 13 articles (01/2021 - 04/2007)
6.	Jones, Nigel P: 12 articles (06/2015 - 10/2002)
7.	Ahn, Chul Woo: 12 articles (09/2008 - 01/2005)
8.	Nuutila, Pirjo: 11 articles (09/2017 - 12/2002)
9.	Zinman, Bernard: 11 articles (07/2011 - 10/2002)
10.	Kravitz, Barbara G: 10 articles (04/2013 - 12/2006)

Related Diseases

1.	Insulin Resistance 06/01/2004 - "Euglycemic hyperinsulinemic clamp studies confirmed that FAT is a good model of insulin resistance and rosiglitazone treatment resulted in a significant improvement in insulin sensitivity. " 11/01/2014 - "Rosiglitazone treatment significantly improved hepatic insulin sensitivity and inhibited the IKK-β, NF-κB, and Ser307p-IRS-1 expressions in the liver (P < 0.05). " 07/01/2014 - "Rosiglitazone treatment significantly improved a number of metabolic parameters of the ASKO mice, including insulin sensitivity. " 06/01/2011 - "Rosiglitazone significantly increased adipocyte reesterification and improved insulin sensitivity, but the potential benefit of these changes was compromised by increase in total lipolysis. " 01/01/2006 - "Insulin sensitivity significantly improved after the addition of rosiglitazone treatment in diabetic patients (p < 0.01). "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2003 - "Rosiglitazone significantly improved HbA(lc) and FPG levels in patients with type 2 diabetes, with the greatest improvements observed in patients with baseline HbA(lc) levels > or =9%." 01/01/2000 - "Overall, the combination of rosiglitazone and a sulphonylurea was safe, well tolerated and effective in patients with Type 2 diabetes." 07/01/2009 - "The aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients. " 09/01/2010 - "These data suggest that the PGC-1α Thr394Thr and Gly482Ser polymorphisms are associated with therapeutic efficacy of multiple-dose rosiglitazone in Chinese patients with type 2 diabetes mellitus." 08/01/2008 - "The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes."
3.	Inflammation (Inflammations) 01/01/2022 - "Inhibition of hyperactive inflammation and proliferation of endogenous neural stem cells (NSCs) is a promising treatment strategy for SCI. Our previous studies demonstrated the beneficial effects of rosiglitazone (Rosi) on SCI, but its roles in inflammation inhibition and proliferation of NSCs are unknown. " 04/01/2008 - "A significant reduction in HOMA-R, markers of inflammation and oxidative stress was only observed with rosiglitazone. " 01/01/2016 - "However, the exact mechanism for the protective effects of rosiglitazone against inflammation such as liver injury remains unclear. " 08/14/2012 - "The protective effects of rosiglitazone against MCT-induced PH are correlated with drug dose and may be due to the inhibition of inflammation." 12/01/2011 - "In addition, adipose mass, adipocyte cross-sectional area and inflammation were improved with rosiglitazone. "
4.	Body Weight (Weight, Body) 09/01/2007 - "Rosiglitazone (Rosi), despite marked improvement in glycaemia, hyperinsulinaemia and hyperlipidaemia, failed to affect SREBP-1 expression, and increased body weight and IMTG. " 08/01/2000 - "The two rexinoids also produced a marked decrease in the body weight gain, whereas the growth rate of rats treated with BRL 49653 tended to increase. " 08/01/2010 - "Compared to placebo, rosiglitazone treated patients had a higher (mean + or - SD) body weight (89 + or - 15 kg vs. 84 + or - 15 kg, P=0.02) at the end of the study, mostly related to an increment in subcutaneous adipose tissue. " 12/01/2023 - "GFW and rosiglitazone treatment suppressed body weight and ovarian weight in PCOS rats. " 11/14/2023 - "No compound showed considerable effect on the body weight of animals after 21 days of administration, and the findings showed statistical difference (p < 0.05 to p < 0.0001) among the diabetic control and standard drug rosiglitazone groups. "
5.	Non-alcoholic Fatty Liver Disease 01/01/2016 - "Rosiglitazone intervention did not activate PPARγ in liver, but improved liver histology and counteracted the expression of genes associated with severe NAFLD in humans. " 01/01/2016 - "In previous studies, it has been reported that rosiglitazone has opposing effects on nonalcoholic fatty liver disease. " 08/01/2007 - "The aim of this study was to analyze the effects of rosiglitazone on the liver histology and mitochondrial function in a model of NAFLD. " 01/01/2023 - "We tested a promising intervention strategy targeting Osr1-PPARγ by AAV8L-delivered Osr1 expression or rosiglitazone that significantly repressed NAFLD/NASH progression in Osr1F and Osr1ΔMφ mice. " 08/24/2018 - "The experiment was divided into control, model (NAFLD), SC formula and rosiglitazone groups (n = 7 in each group). "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Metformin (Glucophage)
3.	Glucose (Dextrose)
4.	Pioglitazone (Actos)
5.	PPAR gamma
6.	Peroxisome Proliferator-Activated Receptors (PPAR)
7.	Lipids
8.	Ligands
9.	Glyburide (Glibenclamide)
10.	Adiponectin

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Aftercare (After-Treatment)
4.	Peritoneal Dialysis
5.	Oral Administration